# US 2026/0241047 A1 · Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0241047 A1
- Document ID: US20260241047A1
- Status: Published application
- Kind: A1
- Application number: 19/375,117
- Filed: 2025-10-30
- Published: 2026-08-20
- Earliest claimed: 2024-03-22
- Assignees: Nuclidium AG; University of Basel
- Applicants: Nuclidium AG; University of Basel
- Inventors: Leila Jaafar-Thiel; Francesco De Rose; Melpomeni Fani; Jacopo Millul
- Web page: https://patentgrep.com/patent/US20260241047A1

## CPC

- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 47/02: Inorganic compounds
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/121: {Solutions, i.e. homogeneous liquid formulation}
- A61P 35/00: Antineoplastic agents
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to pharmaceutical compositions comprising a [61Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

## Claims

### Claim 1

A method for imaging a subject comprising:
(a) administering an effective amount of a pharmaceutical composition to a subject suspected of having or diagnosed with a disorder associated with expression of fibroblast activation protein (FAP), wherein the pharmaceutical composition comprises:
i. a radiotracer that has one of the following structures
Radiotracer
Structure
61Cu-NODAGA-1
61Cu-NODAGA-2
61Cu-NODAGA-3
61Cu-NODAGA-4
or is a pharmaceutically acceptable salt thereof; and
ii. a radiolytic inhibitor;
wherein the pharmaceutical composition is characterized by one or more of:
a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
a radiocobalt activity content at end of synthesis of ≤0.05%,
a 110mAg specific activity ≤0.1 Bq/g,
a 108mAg specific activity ≤0.1 Bq/g, or
a 109Cd specific activity ≤0.1 Bq/g; and
(b) generating one or more radiographic images of the subject.

### Claim 2

(canceled)

### Claim 3

A method for determining a subject's response to a cancer treatment comprising:
(a) administering an effective amount of a pharmaceutical composition to a subject diagnosed with a fibroblast activation protein (FAP)-expressing cancer or tumor at an earlier time point and at a later time point, wherein the pharmaceutical composition comprises:
i. a radiotracer that has one of the following structures
Radiotracer
Structure
61Cu-NODAGA-1
61Cu-NODAGA-2
61Cu-NODAGA-3
61Cu-NODAGA-4
or is a pharmaceutically acceptable salt thereof; and
ii. a radiolytic inhibitor;
wherein the pharmaceutical composition is characterized by one or more of:
a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
a radiocobalt activity content at end of synthesis of ≤0.05%,
a 110mAg specific activity ≤0.1 Bq/g,
a 108mAg specific activity ≤0.1 Bq/g, or
a 109Cd specific activity ≤0.1 Bq/g;
(b) generating one or more radiographic images of the subject at the earlier time point and at the later time point;
(c) determining the amount of localization of the radionuclide in the one or more radiographic images of the subject at the earlier time point and at the later time point; and
(d) determining the subject's response to the cancer treatment by comparing the amount of localization of the radionuclide in the one or more radiographic images of the subject at the earlier time point and at the later time point.

### Claim at position 4

4-54. (canceled)

### Claim 55

A pharmaceutical composition comprising:
(a) a radiotracer that has one of the following structures
Radiotracer
Structure
61Cu-NODAGA-1
61Cu-NODAGA-2
61Cu-NODAGA-3
61Cu-NODAGA-4
or is a pharmaceutically acceptable salt thereof,
(b) a radiolytic inhibitor, and
(c) an aqueous vehicle;
wherein the pharmaceutical composition is characterized by one or more of:
a [61Cu]Cu radionuclidic purity at end of synthesis of ≥97%,
a radiocobalt activity content at end of synthesis of ≤0.05%,
a 110mAg specific activity ≤0.1 Bq/g,
a 108mAg specific activity ≤0.1 Bq/g, or
a 109Cd specific activity ≤0.1 Bq/g.

### Claim 56 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the activity of the pharmaceutical composition is ≥25 MBq.

### Claim 57

(canceled)

### Claim 58 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the radiotracer radiochemical purity of the pharmaceutical composition is ≥90% at 12 hours after end of synthesis.

### Claim 59

(canceled)

### Claim 60 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pharmaceutical composition is characterized by a 61[Cu]Cu radionuclidic purity of the pharmaceutical composition at end of synthesis of ≥98%.

### Claim 61 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pharmaceutical composition is characterized by a radiocobalt activity content at end of synthesis of ≤0.01%.

### Claim 62 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pharmaceutical composition is characterized by at least one of a 56[Co]Co specific activity or 58[Co]Co specific activity of ≤1,500 Bq/g.

### Claim at position 13

63-65. (canceled)

### Claim 66 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pharmaceutical composition is characterized by one or more of: a 110mAg specific activity ≤0.1 Bq/g, a 108mAg specific activity ≤0.1 Bq/g, or a 109Cd specific activity ≤0.1 Bq/g.

### Claim 67 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the sum of the specific activities of the radionuclidic impurities in the pharmaceutical composition is ≤8,000 Bq/g.

### Claim 68 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pharmaceutical composition is characterized by one or more of: Al≤1.2 ng/MBq, Co≤0.2 ng/MBq, Fe≤1.7 ng/MBq, Pb≤0.8 ng/MBq, or Zn≤0.8 ng/MBq.

### Claim 69 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the activity concentration of the pharmaceutical composition is ≥10 MBq/mL.

### Claim 70

(canceled)

### Claim 71 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the apparent molar activity of the radiotracer is ≥1 MBq/nmol.

### Claim 72 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the radiotracer is present in an amount ≥1 μg.

### Claim 73

(canceled)

### Claim 74 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the aqueous vehicle comprises isotonic saline.

### Claim 75 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the radiolytic inhibitor is present in the pharmaceutical composition in a concentration of ≥1 mg/mL.

### Claim 76 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the radiolytic inhibitor is present in the pharmaceutical composition in a concentration from 1 mg/mL to 10 mg/mL.

### Claim 77 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the radiolytic inhibitor is selected from ascorbic acid, gentisic acid, citric acid, N-tert-butyl-α-phenylnitrone (PBN), polyvinylpyrrolidone (PVP), ethanol, DMSA, cysteine, vanillin, methionine, adenine, dobesilic acid, thymine, uracil, nicotinic acid, nicotinamide, salts of any of the foregoing, and combinations thereof.

### Claim 78 (depends on 77)

The pharmaceutical composition according to claim 77, wherein the radiolytic inhibiter is ascorbic acid or a salt thereof.

### Claim 79 (depends on 55)

The pharmaceutical composition according to claim 55, comprising:
1-100 μg of the radiotracer,
5-20 mg of ascorbic acid or a salt thereof, and
1-10 mL isotonic saline solution.

### Claim 80 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the composition is formulated for intravenous infusion.

### Claim 81 (depends on 55)

The pharmaceutical composition of claim 55, wherein the total volume is from 2 mL to 15 mL.

### Claim 82 (depends on 55)

The pharmaceutical composition according to claim 55, having ≥99% radiochemical purity at 3 hours after end of synthesis.

### Claim 83 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the pH is from 5 to 7.
